SARS vaccine development. [Emerg Infect Dis. 2005]

SearchDatabase nameforSearch term

Advanced Search

Your browser version may not work well with NCBI's Web applications. More information here...

Display Show

All: 1

Review: 1

Click to change filter selection through MyNCBI.

1: Emerg Infect Dis. 2005 Jul;11(7):1016-20. Links

SARS vaccine development.

Jiang S, He Y, Liu S.

New York Blood Center, New York, New York 10021, USA. SJiang@NYBloodcenter.org

Developing effective and safe vaccines is urgently needed to prevent infection by severe acute respiratory syndrome (SARS)-associated coronavirus (SARS-CoV). The inactivated SARS-CoV vaccine may be the first one available for clinical use because it is easy to generate; however, safety is the main concern. The spike (S) protein of SARS-CoV is the major inducer of neutralizing antibodies, and the receptor-binding domain (RBD) in the S1 subunit of S protein contains multiple conformational neutralizing epitopes. This suggests that recombinant proteins containing RBD and vectors encoding the RBD sequence can be used to develop safe and effective SARS vaccines.

PMID: 16022774 [PubMed - indexed for MEDLINE]

ReviewVaccine design for severe acute respiratory syndrome coronavirus.
Viral Immunol. 2005; 18(2):327-32.

[Viral Immunol. 2005]
Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.
J Virol. 2006 Jun; 80(12):5757-67.

[J Virol. 2006]
Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine.
Vaccine. 2006 Jun 29; 24(26):5498-508. Epub 2006 May 11.

[Vaccine. 2006]
Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.
Virology. 2005 Mar 30; 334(1):74-82.

[Virology. 2005]
ReviewDevelopment of subunit vaccines against severe acute respiratory syndrome.
Drugs Today (Barc). 2008 Jan; 44(1):63-73.

[Drugs Today (Barc). 2008]
» See reviews... | » See all...

Cited by 6 PubMed Central articles

Molecular targets for diagnostics and therapeutics of severe acute respiratory syndrome (SARS-CoV).
Suresh MR, Bhatnagar PK, Das D. J Pharm Pharm Sci. 2008 Apr 19; 11(2):1s-13s. Epub 2008 Apr 19.

[J Pharm Pharm Sci. 2008]
A Sabin 1 poliovirus-based vaccine vector transfects Vero cells with high efficiency.
Li C, Han W, Zhang Y, Wang J. Cytotechnology. 2007 Jul; 54(3):169-79. Epub 2007 Jul 11.

[Cytotechnology. 2007]
Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection.
Du L, Zhao G, Lin Y, Chan C, He Y, Jiang S, Wu C, Jin DY, Yuen KY, Zhou Y, et al. Vaccine. 2008 Mar 20; 26(13):1644-51. Epub 2008 Feb 4.

[Vaccine. 2008]
» See all...

Recent Activity

Clear Turn Off Turn On

SARS vaccine development.SARS vaccine development.

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

Display Show

SARS vaccine development.

Related articles

Cited by 6 PubMed Central articles

Recent Activity